lncRNA RPPH1 promotes non‑small cell lung cancer progression through the miR‑326/WNT2B axis

Wu,Yuying; Cheng,Kewei; Liang,Wenjun; Wang,Xiaohua

doi:10.3892/ol.2020.11966

lncRNA RPPH1 promotes non‑small cell lung cancer progression through the miR‑326/WNT2B axis

Authors:
- Yuying Wu
- Kewei Cheng
- Wenjun Liang
- Xiaohua Wang
View Affiliations

Affiliations: Department of Respiratory and Critical Care Medicine, The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou, Jiangsu 213000, P.R. China
Published online on: August 10, 2020 https://doi.org/10.3892/ol.2020.11966
Article Number: 105
Copyright: © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Long non‑coding RNAs (lncRNAs) serve important regulatory roles in human tumors. The aim of the present study was to examine the role of ribonuclease P RNA component H1 (RPPH1) in non‑small cell lung cancer (NSCLC). RPPH1 expression was assessed in datasets from The Cancer Genome Atlas, as well as lung cancer cell lines and patients with NSCLC. RPPH1 was significantly upregulated in NSCLC cell lines, compared with a normal lung epithelial cell line. Moreover, high RPPH1 expression was associated with poor overall survival and disease progression. RPPH1 was knocked down in A549 and H1299 cells using short hairpin (sh) RNA constructs, and the expressions of target genes and proteins were determined by reverse transcription‑quantitative PCR and western blotting. Cell invasion potential was also determined using Transwell Matrigel assays. Compared with the negative control, RPPH1 silencing significantly reduced the number of invading cells, increased E‑cadherin expression and reduced vimentin protein expression. Cell resistance to cisplatin/cis‑diamminedichloridoplatinum (CDDP) was also evaluated using Cell Counting Kit‑8 and colony formation assays. RPPH1 overexpression increased the resistance of A549 and H1299 cells to CDDP. Moreover, the potential interactions between RPPH1, microRNA (miR)‑326 and Wnt family member 2B (WNT2B) were investigated using luciferase reporter assays and co‑transfection experiments. MiR‑326 expression was directly inhibited by RPPH1. In A549 cells co‑transfected with shRPPH1 and miR‑326 inhibitor, the invading cell number significantly increased compared with cells transfected with shRPPH1 alone. In addition, E‑cadherin expression levels were reduced, and vimentin was upregulated. MiR‑326 overexpression partially reduced the resistance of A549 cells to CDDP induced by RPPH1 overexpression. WNT2B expression was directly suppressed using miR‑326. A549 cells co‑transfected with a miR‑326 mimic and a WNT2B overexpression vector demonstrated increased invasion potential, reduced E‑cadherin and increased vimentin protein expression levels, compared with cells transfected with the mimic alone. miR‑326 overexpression reduced CDDP resistance in A549 cells. However, co‑transfection with WNT2B partially enhanced CDDP resistance, compared with the mimic alone. In conclusion, RPPH1 promoted NSCLC progression and lung cancer cell resistance to CDDP through miR‑326 and WNT2B.

View Figures

View References

1	Brahmer JR, Govindan R, Anders RA, Antonia SJ, Sagorsky S, Davies MJ, Dubinett SM, Ferris A, Gandhi L, Garon EB, et al: The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). J Immunother Cancer. 6:752018. View Article : Google Scholar : PubMed/NCBI
2	Lei Z, Shi H, Li W, Yu D, Shen F, Yu X, Lu D, Sun C and Liao K: MiR-185 inhibits non-small cell lung cancer cell proliferation and invasion through targeting of SOX9 and regulation of Wnt signaling. Mol Med Rep. 17:1742–1752. 2018.PubMed/NCBI
3	Tanaka F and Yoneda K: Adjuvant therapy following surgery in non-small cell lung cancer (NSCLC). Surg Today. 46:25–37. 2016. View Article : Google Scholar : PubMed/NCBI
4	Sotgia F and Lisanti MP: Mitochondrial markers predict survival and progression in non-small cell lung cancer (NSCLC) patients: Use as companion diagnostics. Oncotarget. 8:68095–68107. 2017. View Article : Google Scholar : PubMed/NCBI
5	Yin D, Lu X, Su J, He X, De W, Yang J, Li W, Han L and Zhang E: Long noncoding RNA AFAP1-AS1 predicts a poor prognosis and regulates non-small cell lung cancer cell proliferation by epigenetically repressing p21 expression. Mol Cancer. 17:922018. View Article : Google Scholar : PubMed/NCBI
6	Guo X, Wei Y, Wang Z, Liu W, Yang Y, Yu X and He J: LncRNA LINC00163 upregulation suppresses lung cancer development though transcriptionally increasing TCF21 expression. Am J Cancer Res. 8:2494–2506. 2018.PubMed/NCBI
7	Pei W, Dong C, Hongbing M and Yong L: Long non-coding RNA MEG3 regulates proliferation and apoptosis in non-small cell lung cancer via the miR-205-5p/LRP1 pathway. Rsc Adv. 7:49710–49719. 2017. View Article : Google Scholar
8	Cai Y, Sun Z, Jia H, Luo H, Ye X, Wu Q, Xiong Y, Zhang W and Wan J: Rpph1upregulates CDC42 expression and promotes hippocampal neuron dendritic spine formation by competing with miR-330-5p. Front Mol Neurosci. 10:272017. View Article : Google Scholar : PubMed/NCBI
9	Zhang P..Sun Y..Peng R..et al: Long non-coding RNA Rpph1 promotes inflammation and proliferation of mesangial cells in diabetic nephropathy via an interaction with Gal-3. Cell Death Dis. 10:5262019. View Article : Google Scholar : PubMed/NCBI
10	Liang ZX, Liu HS, Wang FW, Xiong L, Zhou C, Hu T, He XW, Wu XJ, Xie D, Wu XR and Lan P: LncRNA RPPH1 promotes colorectal cancer metastasis by interacting with TUBB3 and by promoting exosomes-mediated macrophage M2 polarization. Cell Death Dis. 10:8292019. View Article : Google Scholar : PubMed/NCBI
11	Lei B, He A, Chen Y, Cao X, Zhang P, Liu J, Ma X, Qian L and Zhang W: Long non-coding RNA RPPH1 promotes the proliferation, invasion and migration of human acute myeloid leukemia cells through down-regulating miR-330-5p expression. EXCLI J. 18:824–837. 2019.PubMed/NCBI
12	Jiang H, Liang M, Jiang Y, Zhang T, Mo K, Su S, Wang A, Zhu Y, Huang G and Zhou R: The lncRNA TDRG1 promotes cell proliferation, migration and invasion by targeting miR-326 to regulate MAPK1 expression in cervical cancer. Cancer Cell Int. 19:1522019. View Article : Google Scholar : PubMed/NCBI
13	Wang R, Chen X, Xu T, Xia R, Han L, Chen W, De W and Shu Y: MiR-326 regulates cell proliferation and migration in lung cancer by targeting phox2a and is regulated by HOTAIR. Am J Cancer Res. 6:173–186. 2016.PubMed/NCBI
14	Ghaemi Z, Soltani BM and Mowla SJ: MicroRNA-326 functions as a tumor suppressor in breast cancer by targeting ErbB/PI3K signaling pathway. Front Oncol. 9:6532019. View Article : Google Scholar : PubMed/NCBI
15	Liu W, Zhang B, Xu N, Wang MJ and Liu Q: MiR-326 regulates EMT and metastasis of endometrial cancer through targeting TWIST1. Eur Rev Med Pharmacol Sci. 21:3787–3793. 2017.PubMed/NCBI
16	Wang B, Sun L, Li J and Jiang R: MiR-577 suppresses cell proliferation and epithelial-mesenchymal transition by regulating the WNT2B mediated Wnt/β-catenin pathway in non-small cell lung cancer. Mol Med Rep. 18:2753–2761. 2018.PubMed/NCBI
17	Detterbeck FC, Boffa DJ, Kim AW and Tanoue LT: The eighth edition lung cancer stage classification. Chest. 151:193–203. 2017. View Article : Google Scholar : PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
19	Hai J, Zhu CQ, Wang T, Organ SL, Shepherd FA and Tsao MS: TRIM14 is a putative tumor suppressor and regulator of innate immune response in non-small cell lung cancer. Sci Rep. 7:396922017. View Article : Google Scholar : PubMed/NCBI
20	Stinchcombe TE and Socinski MA: Current treatments for advanced stage non-small cell lung cancer. Proc Am Thorac Soc. 6:233–241. 2009. View Article : Google Scholar : PubMed/NCBI
21	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
22	Wang L, Ma L, Xu F, Zhai W, Dong S, Yin L, Liu J and Yu Z: Role of long non-coding RNA in drug resistance in non-small cell lung cancer. Thorac Cancer. 9:761–768. 2018. View Article : Google Scholar : PubMed/NCBI
23	Schmitt AM and Chang HY: Long Noncoding RNAs in cancer pathways. Cancer Cell. 29:452–463. 2016. View Article : Google Scholar : PubMed/NCBI
24	Noh JH, Kim KM, McClusky WG, Abdelmohsen K and Gorospe M: Cytoplasmic functions of long noncoding RNAs. Wiley Interdiscip Rev RNA. 9:e14712018. View Article : Google Scholar : PubMed/NCBI
25	Chen QN, Wei CC, Wang ZX and Sun M: Long non-coding RNAs in anti-cancer drug resistance. Oncotarget. 8:1925–1936. 2017. View Article : Google Scholar : PubMed/NCBI
26	Jiang C, Li X, Zhao H and Liu H: Long non-coding RNAs: Potential new biomarkers for predicting tumor invasion and metastasis. Mol Cancer. 15:622016. View Article : Google Scholar : PubMed/NCBI
27	Xia T, Liao Q, Jiang X, Shao Y, Xiao B, Xi Y and Guo J: Long noncoding RNA associated-competing endogenous RNAs in gastric cancer. Sci Rep. 4:60882014. View Article : Google Scholar : PubMed/NCBI
28	Leonard L, Dachet F, Cai J, Bagla S, Balan K, Jia H and Loeb JA: Activity-dependent human brain coding/noncoding gene regulatory networks. Genetics. 192:1133–1148. 2012. View Article : Google Scholar : PubMed/NCBI
29	Sun C, Huang C, Li S, Yang C, Xi Y, Wang L, Zhang F, Fu Y and Li D: Hsa-miR-326 targets CCND1 and inhibits non-small cell lung cancer development. Oncotarget. 7:8341–8359. 2016. View Article : Google Scholar : PubMed/NCBI
30	Sun Y, Zheng S, Torossian A, Speirs CK, Schleicher S, Giacalone NJ, Carbone DP, Zhao Z and Lu B: Role of insulin-like growth factor-1 signaling pathway in cisplatin-resistant lung cancer cells. Int J Radiat Oncol Biol Phys. 82:e563–e572. 2012. View Article : Google Scholar : PubMed/NCBI
31	Li J, Li S, Chen Z, Wang J, Chen Y, Xu Z, Jin M and Yu W: MiR-326 reverses chemoresistance in human lung adenocarcinoma cells by targeting specificity protein 1. Tumour Biol. 37:13287–13294. 2016. View Article : Google Scholar : PubMed/NCBI
32	Katoh M: Differential regulation of WNT2 and WNT2B expression in human cancer. Int J Mol Med. 8:657–660. 2001.PubMed/NCBI
33	Li SJ, Yang XN and Qian HY: Antitumor effects of WNT2B silencing in GLUT1 overexpressing cisplatin resistant head and neck squamous cell carcinoma. Am J Cancer Res. 5:300–308. 2014.PubMed/NCBI
34	Kobayashi M, Huang CL, Sonobe M, Kikuchi R, Ishikawa M, Kitamura J, Miyahara R, Menju T, Iwakiri S, Itoi K, et al: Intratumoral Wnt2B expression affects tumor proliferation and survival in malignant pleural mesothelioma patients. Exp Ther Med. 3:952–958. 2012. View Article : Google Scholar : PubMed/NCBI
35	Wang H, Fan L, Xia X, Rao Y, Ma Q, Yang J, Lu Y, Wang C, Ma D and Huang X: Silencing Wnt2B by siRNA interference inhibits metastasis and enhances chemotherapy sensitivity in ovarian cancer. Int J Gynecol Cancer. 22:755–761. 2012. View Article : Google Scholar : PubMed/NCBI
36	Jiang H, Li F, He C, Wang X, Li Q and Gao H: Expression of Gli1 and Wnt2B correlates with progression and clinical outcome of pancreatic cancer. Int J Clin Exp Pathol. 7:4531–4538. 2014.PubMed/NCBI
37	Liu C, Li G, Yang N, Su Z, Zhang S, Deng T, Ren S, Lu S, Tian Y, Liu Y and Qiu Y: MiR-324-3p suppresses migration and invasion by targeting WNT2B in nasopharyngeal carcinoma. Cancer Cell Int. 17:22017. View Article : Google Scholar : PubMed/NCBI